CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. (Nasdaq: TENK) filed a 424B3 prospectus supplement with the SEC on May 5, 2026, continuing its post-merger public-company obligations following its business combination with TenX Keane Acquisition Corp, a blank-check special purpose acquisition company that completed its IPO in 2022. Citius Oncology operates in the oncology biopharmaceutical sector and was carved out of Citius Pharmaceuticals prior to the de-SPAC transaction. A 424B3 filing serves as a final prospectus, typically used post-merger for registered resale offerings of outstanding shares. The combined company currently trades on Nasdaq under the ticker TENK. For full filing history, sponsor details, and transaction data on TENK, sign up for complete access at SpacDesk.